Compare Kraft Heinz Co (KHC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs TG Therapeutics Inc — how do they compare? Kraft Heinz Co trades at $25.9 (market cap $30.66B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Kraft Heinz Co is far larger — about 3.7× TG Therapeutics Inc's market cap, and Kraft Heinz Co pays a 6.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KHC | TGTX | |
|---|---|---|
Market Cap | $30.66B | $8.26B |
Sector | Consumer Staples | Health |
52-Week High | $28.94 | $59.06 |
52-Week Low | $21.21 | $26.39 |
Enterprise Value | $47.71B | $8.50B |
Dividend Yield | 6.19% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
